Roche’s Alzheimer’s disease therapy has continued to show benefit for patients after 28 weeks in a long-term extension study. In the high-dose cohort from the ongoing Phase Ib/IIa Brainshuttle AD ...

Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked TCE.

Diakonos Oncology has dosed the first subject in its Phase II trial of investigational patient-derived double-loaded dendritic cell therapy, DOC1021, for treating a highly aggressive brain tumour, ...

Walgreens sets sights on clinical trial network growth in recruitment drive The US pharmacy’s clinical trials business aims to address industry-wide challenges in trial recruitment and diversity.

RSV threat in premature babies could be minimised with immunisation coverage Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

The first patient has been treated with InterVene’s Recana thrombectomy system for restoring patency (blood flow) in chronically obstructed deep veins and venous stents.

Bristol Myers Squibb (BMS) has revealed that its Phase III trial assessing Reblozyl with JAKi therapy did not meet its primary goal.

Ocugen has dosed the first subject in its Phase II/III GARDian3 trial of modifier gene therapy candidate, OCU410ST.

Viatris’ investigational blepharitis ointment failed to achieve the primary endpoint in its Phase III trial, prompting the company to reconsider the drug’s future. The Phase III study (NCT06400511) ...

Industry experts have provided insight into how oncology clinical trials can be designed for success from the outset and rendered as patient-centric as possible. At the Clinical Trials in Oncology ...

Velocity Clinical Research has partnered with Palantir Technologies for streamlining and automating payment reconciliation processes in trials, marking an advancement in the application of AI to ...

Accurate data interpretation key to expanding RWE in trials While barriers to RWD remain, its use in clinical trials increased in 2024, GlobalData analysis shows.